Search Clinical Trials
164 matching studies
| Sponsor Condition of Interest |
|---|
|
Registry of Asthma Characterization and Recruitment 3 (RACR3)
National Institute of Allergy and Infectious Diseases (NIAID)
Asthma
This is a multi-center, non-interventional registry to create and maintain a database of
participants to serve as a recruitment source for current and future DAIT NIAID-sponsored
Childhood Asthma in Urban Settings (CAUSE) studies. expand
This is a multi-center, non-interventional registry to create and maintain a database of participants to serve as a recruitment source for current and future DAIT NIAID-sponsored Childhood Asthma in Urban Settings (CAUSE) studies. Type: Observational [Patient Registry] Start Date: Apr 2022 |
|
An Observational Study of Carbaglu® for the Treatment of MMA and PA in Adults and Pediatrics
RECORDATI GROUP
Hyperammonemia
Methylmalonic Acidemia
Propionic Acidemia
To obtain short-term and long-term clinical safety information, in pediatric and adult
patients with PA and MMA treated with Carbaglu®. expand
To obtain short-term and long-term clinical safety information, in pediatric and adult patients with PA and MMA treated with Carbaglu®. Type: Observational Start Date: Jun 2022 |
|
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progress1
Day One Biopharmaceuticals, Inc.
Low-grade Glioma
Advanced Solid Tumor
This is a Phase 2, multi center, open-label study to evaluate the safety and efficacy of
Type II RAF (tovorafenib) in pediatric participants with low-grade glioma or advanced
solid tumors. Qualifying genomic alterations will be identified through molecular assays
as routinely performed at Clinical1 expand
This is a Phase 2, multi center, open-label study to evaluate the safety and efficacy of Type II RAF (tovorafenib) in pediatric participants with low-grade glioma or advanced solid tumors. Qualifying genomic alterations will be identified through molecular assays as routinely performed at Clinical Laboratory Improvement Amendments (CLIA) of 1988 or other similarly certified laboratories prior to enrollment into any of the arms. The study will consist of a screening period, a treatment period, a long-term extension phase, end of treatment (EOT) visit(s), a safety follow-up visit, and long-term follow-up assessments. Type: Interventional Start Date: Apr 2021 |
|
Feasibility/Acceptability of Attentional-Control Training in Survivors
Children's National Research Institute
Pediatric Cancer
Pediatric ALL
Pediatric Brain Tumor
Attention Difficulties
Cognitive Deficit in Attention
This is a multicenter pilot randomized controlled trial, with an active control
condition, of the feasibility, acceptability, and preliminary efficacy of EndeavorRx in a
cohort of survivors of acute lymphoblastic leukemia or brain tumor ages 8-16 who are > 1
year from the end of therapy. expand
This is a multicenter pilot randomized controlled trial, with an active control condition, of the feasibility, acceptability, and preliminary efficacy of EndeavorRx in a cohort of survivors of acute lymphoblastic leukemia or brain tumor ages 8-16 who are > 1 year from the end of therapy. Type: Interventional Start Date: Jun 2023 |
|
Molecular Analysis of Samples From Patients With Diffuse Intrinsic Pontine Glioma and Brainstem Gli1
Children's National Research Institute
Diffuse Intrinsic Pontine Glioma
Brainstem Glioma
The purpose of this study is to prospectively collect specimens from pediatric patients
with diffuse intrinsic pontine glioma or brainstem glioma, either during therapy or at
autopsy, in order to characterize the molecular abnormalities of this tumor. expand
The purpose of this study is to prospectively collect specimens from pediatric patients with diffuse intrinsic pontine glioma or brainstem glioma, either during therapy or at autopsy, in order to characterize the molecular abnormalities of this tumor. Type: Observational Start Date: Apr 2010 |